A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol - Trial NCT05976503
Access comprehensive clinical trial information for NCT05976503 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yangtze River Pharmaceutical Group Co., Ltd. and is currently Completed. The study focuses on Erectile Dysfunction. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yangtze River Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 1
Dec 19, 2022
Mar 21, 2023
Primary Outcome
Maximum change in systolic blood pressure (SBP),Maximum change in diastolic blood pressure (DBP),Maximum change in pulse,The area under effect-time curve (AUEC0- 4h) of supine SBP,The area under effect-time curve (AUEC0- 4h) of supine DBP,The area under effect-time curve (AUEC0- 4h) of pulse,Peak concentration (Cmax) of Tunodafil and metabolites M459,Area under drug time curve (AUC) of Tunodafil and metabolites M459,Peak concentration (Cmax) of alcohol
Summary
The purpose of this study is primarily to evaluate the effects of simultaneous administration
 of Tunodafil Hydrochloride Tablets with alcohol on blood pressure, pulse rate and
 pharmacokinetics in healthy Chinese male participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05976503
Non-Device Trial